Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma.

ABSTRACT:

Introduction

Immune checkpoint inhibitors (ICIs) have dramatically changed the treatment landscape for advanced melanoma, but their use in older patients remains understudied. An age-related decline in immune function is of concern when treating older patients because host immune factors can influence clinical outcomes with immunotherapy. Therefore, we aimed to evaluate the effectiveness of ICIs in patients 65 years and older.

Methods

Using the SEER-Medicare data, we evaluated survival by first systemic treatment type in a retrospective cohort study of patients aged 65 years and older who were diagnosed with stage IV cutaneous melanoma between 2012 and 2015. Cox proportional hazards regression was used to estimate hazard ratios (HR) and their corresponding 95% confidence int

SUBMITTER: Howell AV 

PROVIDER: S-EPMC12547970 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature